Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RLRichard J. LinAPAllison ParascondolaMGMika Geva

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows the CRP to albumin ratio predicts survival and treatment response in patients with non-Hodgkin's lymphoma undergoing CAR T-cell therapy, suggesting monitoring may be a

Key Points

  • Higher pre-lymphodepletion CRP to albumin ratio is associated with both overall survival and progression-free survival.
  • In multivariable analysis, higher pre-lymphodepletion CAR with a hazard ratio of 1.14 predicts progression-free survival.
  • Observational analysis of 375 patients treated with CAR T-cell therapy at a single institution reveals significant treatment response insights.
  • These findings underscore the importance of inflammatory markers like CRP in assessing treatment outcomes for non-Hodgkin's lymphoma.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d691https://doi.org/10.1182/blood-2025-7090
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma2025
  2. 2Duration of lymphopenia after CAR-T cell therapy is associated with increased risk of non-melanoma skin cancers and decreased survival2025
  3. 3Absolute lymphocyte count is predictive of response to salvage therapies for post-CAR T failure2025
  4. 4A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis2025
  5. 5CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations